Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Prevention and treatment of pediatric obesity: an Endocrine Society clinical practice guideline.

BIBLIOGRAPHIC SOURCE(S)

GUIDELINE STATUS

This is the current release of the guideline.

Endocrine Society clinical guidelines are valid for 3 years, after which time they are revised.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Definitions for the quality of the evidence (+OOO, ++OO, +++O, and ++++); the strength of the recommendation (1 or 2), and the difference between a "recommendation" and a "suggestion" are provided at the end of the "Major Recommendations" field.

The Problem with Obesity

The objective of interventions in overweight and obese children and adolescents is the prevention or amelioration of obesity-related co-morbidities (e.g., glucose intolerance and type 2 diabetes mellitus (T2DM), metabolic syndrome, dyslipidemia, and hypertension).

Diagnosis of Overweight and Obesity

The Task Force recommends the use of the Body Mass Index (BMI) (calculated as weight in kilograms divided by height in meters squared), with the Centers for Disease Control and Prevention (CDC) derived normative percentiles, as the preferred method for the diagnosis of the overweight or obese child (1 | ++00).

The Task Force recommends that a child be diagnosed as overweight if the BMI is in at least the 85th percentile but less than the 95th percentile for age and sex, and as obese if the BMI is in at least the 95th percentile for age and sex (1 | +000).

The Task Force recommends against a routine laboratory evaluation for endocrine causes of obesity in obese children or early to mid-pubertal obese adolescents unless the child's height velocity, assessed in relation to stage of puberty and family background, is attenuated (1 | ++00).

The Task Force recommends referral to a geneticist for children whose obesity has a syndromic etiology, especially in the presence of neurodevelopmental abnormalities (1 | +000).

The Task Force suggests that parents of children who have inexorably gained weight from early infancy and have risen above the 97th percentile for weight by 3 years of age be informed of the availability of melanocortin 4 receptor (MC4R) genetic testing. However, the test is positive in only 2–4% of such patients who are above the 97th percentile for weight and currently will not alter treatment (2 | +000).

The Task Force recommends that children with a BMI in at least the 85th percentile be evaluated for associated co-morbidities and complications (1 | +000). See "Table 1: Screening Tests for the More Common Obesity Co-Morbidities" and Figure 1 "Diagnosis and Management Flow Chart" in the original guideline document for more detailed information.

Treatment of Obesity

Lifestyle Recommendations

The Task Force recommends that clinicians prescribe and support intensive lifestyle (dietary, physical activity, and behavioral) modification for the entire family and the patient in an age-appropriate manner and as the prerequisite for all overweight and obesity treatments for children and adolescents (1 | +000).

Dietary Recommendations

The Task Force recommends that clinicians prescribe and support healthy eating habits such as:

  • Avoiding the consumption of calorie-dense, nutrient-poor foods (e.g., sweetened beverages, sports drinks, fruit drinks and juices, most "fast food," and calorie-dense snacks) (1 | ++00).

The Task Force suggests that clinicians prescribe and support:

Physical Activity Recommendations

The Task Force recommends that clinicians prescribe and support 60 min of daily moderate to vigorous physical activity (1 | ++00).

The Task Force suggests that clinicians prescribe and support a decrease in time spent in sedentary activities, such as watching television, playing video games, or using computers for recreation. Screen time should be limited to 1–2 hours per day, according to the American Academy of Pediatrics (2 | +000).

Psychosocial Recommendations

The Task Force suggests that clinicians educate parents about the need for healthy rearing patterns related to diet and activity. Examples include parental modeling of healthy habits, avoidance of overly strict dieting, setting limits of acceptable behaviors, and avoidance of using food as a reward or punishment (2 | +000).

The Task Force suggests that clinicians probe for and diagnose unhealthy intrafamily communication patterns and support rearing patterns that seek to enhance the child's self-esteem (2 | +000).

Pharmacotherapy Recommendations

The Task Force suggests that pharmacotherapy (in combination with lifestyle modification) be considered if a formal program of intensive lifestyle modification has failed to limit weight gain or to mollify comorbidities in obese children. Overweight children should not be treated with pharmacotherapeutic agents unless significant, severe co-morbidities persist despite intensive lifestyle modification. In these children, a strong family history of Type 2 Diabetes Mellitus or cardiovascular risk factors strengthens the case for pharmacotherapy (2 | +000).

The Task Force suggests that pharmacotherapy be offered only by clinicians who are experienced in the use of anti-obesity agents and are aware of the potential for adverse reactions (2 | +000).

Bariatric Surgery Recommendations

The Task Force suggests that bariatric surgery be considered only under the following conditions:

  1. The child has attained Tanner 4 or 5 pubertal development and final or near-final adult height.
  2. The child has a BMI greater than 50 kg/m2 or has BMI above 40 kg/m2 and significant, severe comorbidities.
  3. Severe obesity and co-morbidities persist despite a formal program of lifestyle modification, with or without a trial of pharmacotherapy.
  4. Psychological evaluation confirms the stability and competence of the family unit.
  5. There is access to an experienced surgeon in a medical center employing a team capable of long term follow-up of the metabolic and psychosocial needs of the patient and family, and the institution is either participating in a study of the outcome of bariatric surgery or sharing data.
  6. The patient demonstrates the ability to adhere to the principles of healthy dietary and activity habits (2 | ++00).

The Task Force recommends against bariatric surgery for preadolescent children, for pregnant or breastfeeding adolescents, and for those planning to become pregnant within 2 years of surgery; for any patient who has not mastered the principles of healthy dietary and activity habits; for any patient with an unresolved eating disorder, untreated psychiatric disorder, or Prader-Willi syndrome (1 | ++00).

Prevention of Obesity

The Task Force recommends breast-feeding for a minimum of 6 months (1 | ++00).

The Task Force suggests that clinicians promote and participate in efforts to educate children and parents by means of ongoing anticipatory guidance about healthy dietary and activity habits and, further, that clinicians encourage school systems to provide adequate health education courses promoting healthy eating habits (2 | ++00).

The Task Force suggests that clinicians promote and participate in efforts to educate the community about healthy dietary and activity habits (2 | +000).

Societal Barriers to Implementation

The Task Force suggests that clinicians advocate:

  • For regulatory policies designed to decrease the exposure of children and adolescents to the promotion of unhealthy food choices in the community (e.g., by media advertisements targeting children and adolescents) (2 | +000).
  • That school districts ensure that only nutritionally sound food and drinks are available to children in the school environment, including the school cafeteria and alternative sources of food such as vending machines (2 | +000).
  • For parental participation in the design of school-based dietary or physical activity programs and that schools educate parents about the rationale for these programs to ensure their understanding and cooperation (2 | +000).
  • That community master planners design, redesign, and organize communities to maximize opportunities for safe walking or cycling to school, recreational activity and athletic events, and neighborhood shopping as a means to encourage greater physical activity (2 | +000).
  • That clinicians advocate that policymakers provide incentives to ensure that retailers can offer affordable, high-quality fresh fruits and vegetables to all (2 | +000).

Definitions:

Strength of Recommendations

1 - Indicates a strong recommendation and is associated with the phrase "The Task Force recommends."

2 - Denotes a weak recommendation and is associated with the phrase "The Task Force suggests."

Quality of the Evidence

+OOO Denotes very low quality evidence

++OO Denotes low quality evidence

+++O Denotes moderate quality evidence

++++ Denotes high quality evidence

CLINICAL ALGORITHM(S)

A clinical algorithm was provided in the original guideline document (Figure 1) for the diagnosis and management of pediatric obesity.

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is specifically stated for each recommendation (see the "Major Recommendations" field).

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2008 Dec

GUIDELINE DEVELOPER(S)

The Endocrine Society - Disease Specific Society

SOURCE(S) OF FUNDING

The Endocrine Society

GUIDELINE COMMITTEE

Pediatric Obesity Task Force

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Task Force Members: Gilbert P. August; Sonia Caprio; Ilene Fennoy; Michael Freemark; Francine R. Kaufman; Robert H. Lustig; Janet H. Silverstein; Phyllis W. Speiser; Dennis M. Styne; Victor M. Montori

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Gilbert P. August, M.D. (Chair)—Significant Financial Interests: none declared; Governance: none declared; Consultation or Advisement: none declared; Grant or Other Research Support: none declared.

Sonia Caprio, M.D.—Significant Financial Interests: none declared; Governance: none declared; Consultation or Advisement: none declared; Grant or Other Research Support: none declared.

Ilene Fennoy, M.D., MPH—Significant Financial Interests: none declared; Governance: none declared; Consultation or Advisement: Novo Nordisk Turner's Syndrome Advisory Committee (2005); Grant or Other Research Support: Novo Nordisk Answer Program, Serono—Cod Click Adolescent Transition Study, Unimed—Androgel in Male Hypogonadal Puberty Study.

Michael Freemark, M.D.—Significant Financial Interests: none declared; Governance: none declared; Consultation or Advisement: none declared; Grant or Other Research Support: none declared.

Francine R. Kaufman, M.D.—Significant Financial Interests: none declared; Governance: none declared; Consultation or Advisement: Medtronic, Lifescan, Omnipod, Mannkind, Novo Nordisk; Grant or Other Research Support: GSK, Medtronic.

Robert H. Lustig, M.D.—Significant Financial Interests: none declared; Governance: none declared; Consultation or Advisement: Novo Nordisk Pharmaceuticals; Grant or Other Research Support: EndoVx, Inc., Novartis Pharmaceuticals Corp.

Janet H. Silverstein, M.D.—Significant Financial Interests: none declared; Governance: none declared; Consultation or Advisement: Advisory board member for the Genentech Center for Clinical Research in Endocrinology; Grant or Other Research Support: none declared.

Phyllis W. Speiser, M.D.—Significant Financial Interests: none declared; Governance: none declared; Consultation or Advisement: none declared; Grant or Other Research Support: Speakers Bureau—Lilly, Pfizer, and Investigator—Lilly, Genetech, Novo Nordisk, Pfizer, Serono.

Dennis M. Styne, M.D.—Significant Financial Interests: none declared; Governance: none declared; Consultation or Advisement: Healthy Living Academy; Grant or Other Research Support: none declared.

*Victor M. Montori, M.D.—Financial or Business/Organizational Interests: none declared; Significant Financial or Leadership Position: none declared; Consultation/Advisement: KER Unit (Mayo Clinic).

*Evidence-based reviews for this guideline were prepared under contract with The Endocrine Society.

ENDORSER(S)

Lawson Wilkins Pediatric Endocrine Society - Medical Specialty Society

GUIDELINE STATUS

This is the current release of the guideline.

Endocrine Society clinical guidelines are valid for 3 years, after which time they are revised.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from The Endocrine Society.

Print copies: Available from The Endocrine Society, c/o Bank of America, P.O. Box 630721, Baltimore, MD 21263-0736; Phone: (301) 941.0210; Email: Societyservices@endo-society.org

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

PATIENT RESOURCES

The following is available:

  • Patient guide to the prevention and management of pediatric obesity. Chevy Chase (MD): The Hormone Foundation; 2008 Dec. 2 p.

Electronic copies: Available in Portable Document Format (PDF) from The Hormone Foundation Web site.

Print copies: Available from The Endocrine Society, c/o Bank of America, P.O. Box 630721, Baltimore, MD 21263-0736; Phone: (301) 941.0210; Email: Societyservices@endo-society.org

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC STATUS

This NGC summary was completed by ECRI Institute on March 4, 2009. The information was verified by the guideline developer on April 6, 2009.

COPYRIGHT STATEMENT

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo